The Relationships between cyclin D1 Expression and Prognosis of Non-small Cell Lung Cancer

BACKGROUND AND OBJECTIVE: cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in tumorigenesis, invasion and metastasis. We performed a retrospective study on the cyclin D1 expression in non-small cell lung cancer (NSCLC) according to the clinical characteristics. METHODS: One hundred fifteen postsurgical NSCLC patients were investigated. Immunohistochemistry was used to evaluate the cyclin D1 expression. RESULTS: Overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1 low expression of tumors (χ(2)=5.132, P=0.023). In early stage patients (stage Ⅰ, Ⅱ), the overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1-low expression of tumors (χ(2)=6.863, P=0.009). cyclin D1 status (hazard ratio=0.630;P=0.035), differentiation (hazard ratio=0.399; P < 0.001), and pTNM (hazard ratio=1.576; P < 0.001) to be independent prognostic factors for NSCLC patients. Specifically, the cyclin D1 status (hazard ratio=0.188;P=0.008) was a significant prognostic factor for patients with stage Ⅰ NSCLCs. CONCLUSION: cyclin D1 expression is an independent prognosis factor for postoperative patient in stage Ⅰ, Ⅱ NSCLCs.